Vaccinated patients diagnosed with NSCLC who survived the 5 years of the study characterized by a high positive correlation between the level of anti-pneumococcal antibodies and the level of IgG2 (R = 0.698) and IgG3 (R = 0.641), as well as the percentage of total CD19+ peripheral blood plasmablasts (R = 0.627) and IgD -CD19+CD27+++ in CD19+ (R = 0.614), which was maintained throughout the study. Here, CD19 is linked to non-small cell lung carcinoma.